Clinical Trials for Non-Small Cell Lung Cancer

A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults (ECOG 0-2) with locally advanced or metastatic cancers eligible for atezolizumab, investigating therapeutic drug monitoring-based personalized dosing of atezolizumab (anti-PD-L1 immune checkpoint inhibitor) as monotherapy or combined with other approved agents. Patients initially receive standard dosing, then transition to adaptive, lower-frequency fixed dosing based on plasma levels.

ClinicalTrials.gov ID: NCT06066138

A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of ACTM-838 as a Single Agent in Patients With Advanced Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced solid tumors who have exhausted standard treatment options, testing the investigational single-agent ACTM-838 (mechanism of action not specified) as monotherapy. Eligible patients must have measurable disease, good performance status, adequate organ function, and CD4 counts >500/mL.

ClinicalTrials.gov ID: NCT06336148

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with metastatic NSCLC or extensive stage SCLC who have progressed after at least one line of systemic therapy and are eligible for gemcitabine/docetaxel; participants receive weekly ADI-PEG 20 (a pegylated arginine deiminase that depletes extracellular arginine), combined with gemcitabine and docetaxel, followed by ADI-PEG 20 maintenance.

ClinicalTrials.gov ID: NCT05616624

A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with stage IV non-small cell lung cancer and well-controlled HIV on antiretroviral therapy who have not received prior systemic therapy for metastatic disease, and treats them with platinum-based doublet chemotherapy in combination with durvalumab (anti-PD-L1 antibody) and tremelimumab (anti-CTLA-4 antibody). Maintenance durvalumab (with or without pemetrexed for non-squamous histology) is given to responders after induction.

ClinicalTrials.gov ID: NCT04499053

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including SCLC, NSCLC, ESCC, CRPC, melanoma, HCC, cervical cancer, HNSCC, and select rare cancers—who have progressed after or are intolerant to standard therapies. Patients receive DB-1311, an anti-B7-H3 antibody-drug conjugate linked to a topoisomerase I inhibitor, administered intravenously every 3 weeks.

ClinicalTrials.gov ID: NCT05914116

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced solid tumors harboring KRAS G12C mutations—particularly pancreatic, breast, uterine, or epithelial ovarian cancers, and non-small cell lung cancer with combined KRAS G12C and KEAP1 mutations—who have progressed after prior therapy, and treats them with the combination of adagrasib (a selective irreversible KRAS G12C inhibitor) and olaparib (a PARP inhibitor).

ClinicalTrials.gov ID: NCT06130254

An Open-label Phase 1 Study of ASP4396 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic solid tumors harboring the KRAS G12D mutation who have received or declined standard therapies, treating them with ASP4396, a first-in-class intravenous inhibitor designed to block abnormal KRAS G12D signaling. Patients must have measurable disease, ECOG 0-1, and meet specific organ function and exclusion criteria.

ClinicalTrials.gov ID: NCT06364696

A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of DCC-3084 as Monotherapy and in Combination With Other Antitumor Agents in Participants With Advanced Malignancies Driven by the MAPK Pathway

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors driven by MAPK pathway alterations (KRAS, HRAS, NRAS, BRAF, CRAF, or NF1), who have exhausted standard therapies and have good performance status, to receive the investigational oral MAPK pathway inhibitor DCC-3084 as monotherapy or in combination with other antitumor agents. Confirmed BRAF mutations are required for participation in certain cohorts.

ClinicalTrials.gov ID: NCT06287463

KB707-02: a Phase 1/2 Study of Inhaled KB707 in Patients with Advanced Solid Tumor Malignancies Affecting the Lungs

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This study enrolls adults with advanced (stage 3 or 4) NSCLC or other solid tumors affecting the lungs who have progressed after, are intolerant of, or have refused standard therapy, and who have measurable lung lesions and good performance status. Treatment is with inhaled KB707, a gene therapy delivering IL-12 and IL-2 via a non-integrating HSV-1 vector to enhance local anti-tumor immunity, either as monotherapy or in combination with pembrolizumab and/or chemotherapy.

ClinicalTrials.gov ID: NCT06228326

Phase II Trial of Photon Craniospinal Irradiation for Leptomeningeal Disease Secondary to Solid Tumor Malignancy

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with leptomeningeal disease secondary to breast cancer or non-small cell lung cancer who have adequate performance status and organ function, and treats them with photon craniospinal irradiation using VMAT, an advanced conformal radiation therapy technique. All patients receive 10 fractions of CSI over 10 to 20 days to assess efficacy and safety in controlling central nervous system progression.

ClinicalTrials.gov ID: NCT06910761